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PreviewsGetting to the heart of COX-2 inhibition
Aspirin protects against heart disease, while COX-2 Inhibitors appear to injure the heart. The studies by Francois et al.
(2005 [this Issue of Cell Metabolism]) shed light on two distinct prostaglandin receptors contributing to these conflicting
cardiovascular effects.It has become increasingly evident that
cyclooxygenase inhibitors have differing
effects on the cardiovascular system.
The studies of Francois et al. (2005) im-
plicate two specific prostaglandin re-
ceptors in the cardioprotective-versus-
injurious effects of prostaglandins: the
thromboxane or TP receptor and the
prostacyclin or IP receptor.
Prostaglandins are a family of 20-car-
bon oxygenated fatty acids, synthesized
throughout the body, where they exert
diverse local biologic effects. Aspirin
and nonsteroidal anti-inflammatory drugs
(NSAIDs), including ibuprofen, diclo-
fenac, and naproxen, exert their thera-
peutic effects, reducing fever, pain, and
inflammation, by blocking cyclooxygen-
ase-mediated synthesis of prostaglan-
dins. Following their synthesis via a cyclo-
oxygenase isoform (COX-1 or COX-2)
dependent step, prostaglandins E2, F2,
D2, and thromboxane A2 and I2 (prosta-
cyclin) are secreted from cells, where
they bind to locally accessible, ligand-
specific cell surface G protein-coupled
prostanoid receptors respectively desig-
nated EP, FP, DP, TP, or IP. NSAID-like,
antipyretic, analgesic, and anti-inflam-
matory phenotypes have been observed
in mutant knockout mice lacking indivi-
dual prostanoid receptors including IP,
EP2, EP3, and EP1 (Kobayashi and
Narumiya, 2002).
While the therapeutic effects of
NSAIDs are well established, their long-
term use is unfortunately associated
with gastrointestinal (G.I.) bleeding and
adverse cardiovascular side effects, in-
cluding high blood pressure, edema,
and congestive heart failure (Page and
Henry, 2000). COX-2-selective inhibitors
(COXIBs) were introduced to the clinic to
prevent the associated G.I. bleeding;
however, this has brought renewed
scrutiny to the cardiovascular complica-
tions of long-term NSAID and COXIB
use (Fitzgerald, 2004). Results from
prospective, placebo-controlled trials
demonstrate that long-term use of ro-
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pCELL METABOLISM : SEPTEMBER 2005 · VOL.ecoxib and celecoxib are not only asso-
iated with hypertension but also with
ncreased thrombotic events including
yocardial infarction and stroke (Bresa-
ier et al., 2005). Recent studies suggest
hat similar cardiovascular effects are
lso seen with nonselective NSAIDs
Hippisley-Cox and Coupland, 2005).
At first glance, these findings are diffi-
ult to reconcile with the cardio-protec-
ive effects of low-dose aspirin, an irre-
ersible cyclooxygenase inhibitor widely
ecommended for the prevention of car-
iovascular disease (Patrono, 1998).
owever, a detailed consideration of the
vailable information reveals important
ifferences between low-dose aspirin
nd NSAIDs. Because aspirin irrevers-
bly inactivates cyclooxygenases, the
ucleus-bereft platelet cannot replenish
nactivated cyclooxygenase. Thus low-
ose aspirin irreversibly inhibits COX-1-
erived platelet prostaglandin produc-
ion—predominantly thromboxane—as
hey pass through the portal circulation
FitzGerald et al., 1983). In contrast,
SAIDs broadly (but reversibly) inhibit
rostaglandin production in all tissues,
ncluding not only thromboxane but also
rostacyclin and PGE2, vasodilators that
lso exert natriuretic effects within the
idney. Inhibition of PGI2 and PGE2
ynthesis contributes to increased vaso-
ressor tone and renal sodium absorp-
ion, leading to edema and hyper-
ension.
Equally notable is the observation that
OX-2-selective inhibitors leave COX-1-
ependent, platelet-derived thrombox-
ne synthesis intact but potently inhibit
ystemic prostacyclin production (Mc-
dam et al., 1999). A simplified sum-
ary of these results would lead one to
onclude that low-dose aspirin inhibits
roduction of the pressor and prothrom-
otic prostanoid thromboxane but not
he antithrombotic, vasodepressor pros-
acyclin. In contrast, COX-2 inhibitors do
he opposite, inhibiting prostacyclin but
ot thromboxane (Fitzgerald, 2004). Is it
ossible that imbalanced inhibition of
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ension or cardiac fibrosis as well?
In this issue of Cell Metabolism, Fran-
ois et al. examined the consequences
f sustained prostacyclin receptor inac-
ivation using IP receptor knockout mice.
n agreement with other studies (Wata-
abe et al., 2005), IP knockout mice ex-
ibited increased blood pressure on a
igh-sodium diet when compared to
ild-type controls. The authors went on
o show that with increased age of IP−/−
ice comes increased cardiac fibrosis.
hile correction of hypertension pre-
ented cardiac fibrosis in the IP−/− mice,
irect cardiac effects of the IP receptor
lso seem likely since IP−/− mice have
ecently been found to exhibit enhanced
ardiac hypertrophy and fibrosis follow-
ng banding of the aorta, compared to
ild-type mice (Hara et al., 2005). The
tudies by Francois et al. also implicate
he TP receptor in the deleterious re-
ponse to hypertension since simulta-
eous deletion of the TP receptor pre-
ented cardiac fibrosis associated with
oss of the IP receptor without correcting
he associated hypertension (Figure 1).
Whether COX-1, COX-2, or both are
he source of the pro-fibrotic ligand acti-
ating the thromboxane receptor or the
rotective prostacyclin activating the IP
eceptor remains unknown. It is intrigu-
ng that COX-2 inhibitors selectively de-
rease urinary prostacyclin metabolite
xcretion in humans (McAdam et al.,
999). Furthermore, initial studies in
OX-2−/− mice observed cardiac fibrosis
Dinchuk et al., 1995). It will be important
o determine whether chronic COX-2-
elective inhibition leads to similar cardiac
ibrosis as COX-2 or IP-receptor gene
eletion.
It will be equally important to deter-
ine whether the cellular source of TP-
eceptor ligand (i.e., PGH2 or thrombox-
ne) is the circulating platelet or resident
ardiac cells. If the platelet is the source,
ne might predict that low-dose aspirin
hould protect against fibrosis in the IP−/−149
P R E V I E Wmouse. Conversely, if other cells synthe-
size the prostanoids activating the TP
receptor, thromboxane synthesis inhibi-
tors or receptor antagonists might pro-
vide an effective therapeutic approach
to heart disease in patients taking
NSAIDs. Ultimately, through the dissec-
tion of these intricate pathways, it may
b
v
a
e
m
a
o
i150e possible to identify drugs that pro-
ide all the therapeutic effects of NSAIDs
nd COXIBS but lack their adverse side
ffects. Until that time, one can only
arvel at the combination of therapeutic
nd cardioprotective effects of nature’s
wn compound, salicylate, and its chem-
cally modified derivative, aspirin (Figure 1).
(
P
1
P
W
U
(
DFigure 1. Normally, increased dietary salt does not increase blood pressure, in part due to the protective
effects of prostacyclin (PGI2) and IP receptor activation
In mice lacking the IP receptor, increased BP and cardiac fibrosis ensue. The fibrosis depends on thrombox-
ane-receptor activation since it does not occur in mice lacking the TP receptor. This pathway might contribute
to the cardio-protective effects of low-dose aspirin, which inhibits thromboxane synthesis and injurious effects
of COX-2 inhibitors, which in turn inhibits prostacyclin production.
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